Piper Jaffray Raises Price Target On Endo Pharmaceuticals (ENDP)

Piper Jaffray analysts said in a research report released this morning that they are raising their price target on shares of Endo Pharmaceuticals. The firm has a Neutral rating on the stock, and a price target of $26. The previous price target was $25. The change is a result of last week's settlement agreements with Impax and Sandoz for generic versions of Opana ER. Piper's price target is based on 9x 2014 EPS estimates of $3.83 discounted at 11%. Endo Pharmaceuticals Holdings Inc. (ENDP) is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, manufacturing, marketing and sales of branded and generic pharmaceutical products used primarily to treat and manage pain, overactive bladder, prostate and bladder cancer. During today's trading session, ENDP has gained 0.67% to $21.75. See Some of the Top Moving Indexes Here.